Malignant Pleural Mesothelioma Pipeline Therapeutics Development Review H2 2015

Press Release   •   Dec 11, 2015 09:32 EST

This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Malignant Pleural Mesothelioma” addition with 51 market data tables and 14 figures, spread across 248 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

Aduro BioTech, Inc., Advantagene, Inc., Amphera BV, AnGes MG, Inc., ArQule, Inc., Bayer AG, Biogen, Inc., Bionomics Limited, Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, CanBas Co., Ltd., Concordia Healthcare Corp., EnGeneIC Ltd, F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., Genelux Corporation, GlaxoSmithKline Plc, Juno Therapeutics Inc., MedImmune, LLC, Merck & Co., Inc., MolMed S.p.A., Morphotek, Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., Oxford BioMedica Plc, Pfizer Inc., Pharma Mar, S.A., Polaris Pharmaceuticals, Inc., Synta Pharmaceuticals Corp., Verastem, Inc. and Virttu Biologics Limited

Drugs Profile Discussed in this Research:

Ad5-SGE-REIC/Dkk3, amatuximab, anetumab ravtansine, ascrinvacumab, bevacizumab, BG-00001, BMS-986148, BNC-105, CBP-501, Cell Therapy 1 for Oncology, Cell Therapy for Malignant Pleural Mesothelioma and Advanced Leukemia, CRS-207, FP-1039, ganetespib, GEN-0101, Gene Therapy for Malignant Pleural Mesothelioma, Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma, GLONC-1, GSK-2256098, HSV-1716, iCasp9M28z, JTCR-016, MesoCancerVac, MesoCART, Monoclonal Antibody Conjugated to Target Mesothelin for Oncology, napabucasin, NGR-hTNF, nintedanib, nivolumab, pegargiminase, pembrolizumab, porfimer sodium, rAd-IFN, Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer, TargomiRs, tivantinib, trabectedin, tremelimumab, TroVax and VS-5584

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)


  • The report provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Malignant Pleural Mesothelioma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Malignant Pleural Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Malignant Pleural Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Malignant Pleural Mesothelioma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Diseases & treatment Market.

There are different types of diseases & treatment methods available to suit the different needs. In fact, there are different branches of medical science that deal with the different types of diseases. While cardiology deals with the problems related to heart, dermatology can help you with various skin related problems. Visiting one of the specialists in the field is very much advisable when confronted with a disease. Often on the occurrence of a problem, it is best to visit a physician who can diagnose the disease and suggest you the specialist you must visit for the specific treatment. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries